HIV-associated neuropathic pain: Epidemiology, pathophysiology and management

CNS Drugs

Volumn 19, Issue 4, 2005, Pages 325-334

  Verma, Susama ^a   Estanislao, Lydia ^a   Simpson, David ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ACETYLCARNITINE; AMFEBUTAMONE; AMITRIPTYLINE; ANTIRETROVIRUS AGENT; CAPSAICIN; CARBAMAZEPINE; CHLORAMPHENICOL; CISPLATIN; CITALOPRAM; CLONAZEPAM; COCODAMOL; CYTOKINE; DESIPRAMINE; DIDANOSINE; DNA DIRECTED DNA POLYMERASE GAMMA; ETHAMBUTOL; FENTANYL; GABAPENTIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HYDROCODONE; IBUPROFEN; INTERLEUKIN 1; INTERLEUKIN 6; ISONIAZID; LAMOTRIGINE; LIDOCAINE; LOCAL ANESTHETIC AGENT; METRONIDAZOLE; MEXILETINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NORTRIPTYLINE; OXCARBAZEPINE; PACLITAXEL; PARACETAMOL; PAROXETINE; PHENYTOIN; PYRIDOXINE; STAVUDINE; THALIDOMIDE; TOPIRAMATE; TRAMADOL; TUMOR NECROSIS FACTOR ALPHA; VENLAFAXINE; VINBLASTINE; VINCRISTINE; ZALCITABINE;

ACUPUNCTURE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EXAMINATION; CLINICAL FEATURE; DISTAL SYMMETRICAL POLYNEUROPATHY; ELECTROMYOGRAM; FEEDBACK SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; MEDITATION; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RELAXATION TRAINING; REVIEW; SKIN BIOPSY; TRANSCUTANEOUS NERVE STIMULATION;

DISEASE MANAGEMENT; HIV INFECTIONS; HIV-1; HUMANS; POLYNEUROPATHIES;

EID: 17844368598     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200519040-00005     Document Type: Review

References (94)

1. Mendell JR, Sahenk Z. Painful sensory neuropathy. N Engl J Med 2003; 348: 1243-55
2. Estanislao L, Carter K, McArthur J, et al. A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy. J Acquir Immune Defic Syndr 2004 Dec; 37 (5): 1584-6
3. Schifitto G, McDermott MP, McArthur JC, et al. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002 Jun 25; 58 (12): 1764-8
4. Simpson DM. Selected peripheral neuropathies associated with human immunodeficiency virus infection and antiretroviral therapy. J Neurovirol 2002; 8 (2) Suppl. 1: 33-41
5. Newshan G. Pain in human immunodeficiency virus disease. Semin Oncol Nurs 1997 Feb; 13 (1): 36-41
6. Breitbart W, Rosenfeld BD, Passik SD, et al. The undertreatment of pain in ambulatory AIDS patients. Pain 1996 May-Jun; 65 (2-3); 243-9
7. Verma S, Estanislao L, Mintz L, et al. Controlling neuropathic pain in HIV. Curr Infec Dis Rep 2004; 6: 237-42
8. National Institute of Allergy and Infectious Disease. HIV/AIDS Statistics. January 2004. National Institutes of Health. Bethesda (MD); US Department of Health and Human Services Public Health Service, 2004
9. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002 Dec; 8 Suppl. 2: 115-21
10. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003, 77
11. Wang C, Vlahov D, Galai N. et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004 Sep 15; 190 (6): 1046-1054. Epub 2004 Aug 17
12. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002 Dec; 8 Suppl. 2: 115-21
13. Williams D, Geraci A, Simpson DM. AIDS and AIDS-treatment neuropathies. Curr Neurol Neurosci Rep 2001 Nov; 1 (6): 533-8
14. So YT, Holtzman DM, Abrams DI, et al. Peripheral neuropathy associated with acquired immunodeficiency syndrome: prevalence and clinical features from a population-based survey. Arch Neurol 1988 Sep; 45 (9): 945-8
15. Geraci A, Simpson D. Neurological manifestations of HIV-1 infection in the HAART era. Compr Ther 2001; 27: 232-41
16. Childs EA, Lyles RH, Seines OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999; 52: 607-13
17. Simpson DM, Tagliati N. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retroviral 1995; 9: 153-61
18. Martin C, Solders G, Göran MD, et al. Antiretroviral therapy may improve sensory function in HIV-infected patients: a pilot study. Neurology 2000; 54 (11): 2120-7
19. Morgello S, Estanislao L, Simpson D, et al., on behalf of the Manhattan HIV Brain Bank. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol 2004; 4: 546-51
20. Schifitto G, McDermott MP, McArthur JC. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002; 58 (12): 1764-8
21. Savasta AM. HIV: associated transmission risks in older adults. An integrative review of the literature. J Assoc Nurses AIDS Care 2004; 15 (1): 50-9
22. Lopez OL, Becker JT, Dew MA, et al. Risk modifiers for peripheral sensory neuropathy in HIV infection/AIDS. Eur J Neurol 2004; 11 (2): 97-102
23. Kieburtz KD, Giang DW, Schiffer RB, et al. Abnormal vitamin B12 metabolism in human immunodeficiency virus infection: association with neurological dysfunction. Arch Neurol 1991 Mar; 48 (3): 195-207
24. Verucchi G, Calza L, Manfredi R, et al. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 2004; 32 (1): 33-46
25. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with Hepatitis C virus infection: a prospective multicenter study of 321 patients. Medicine 2000; 79: 47-56
26. Cherry CL, McArthur JC, Hoy JF, et al. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol 2003 Feb; 26 (2): 195-207
27. Biehl J, Skavlem J. Toxicity of isoniazid. Am Rev Tuberc 1953; 68: 296-7
28. Gammon GD, Burge FW, King G. Neural toxicity in patients treated with isoniazid. AMA Arch Neurol Psychiatry 1953; 70: 64-9
29. Jones W, Jones G. Peripheral neuropathy due to isoniazid: report of two cases. Lancet 1953; I: 1073-4
30. Berger A, Schaumburg H, Schroeder C, et al. Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity. Neurology 1992; 42: 1367-70
31. Tugwell P, James S. Peripheral neuropathy with ethambutol. Postgrad Med J 1972; 48 (565): 667-70
32. Coxon A, Pallis C. Metronidazole neuropathy. J Neurol Neurosurg Psychiatry 1976; 39: 403-5
33. Dreger L, Gleason P, Chowdhry T, et al. Intermittent-dose metronidazole-induced peripheral neuropathy. Ann Pharmacother 1998; 32: 267-8
34. Sahenk S, Brady S, Mendell J. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve 1987; 10: 80-4
35. Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther 2003; 2: 342-95
36. Fullerton P, O'Sullivan D. Thalidomide neuropathy: a clinical, electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatry 1968; 31: 543-51
37. Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol 2001; 429 (1-3): 23-37
38. DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 2001; 90: 1-6
39. Sorkin LS, Puig S, Jones DL. Spinal bicuculline produces hypersensitivity of dorsal horn neurons: effects of excitatory amino acid antagonists. Pain 1998 Aug; 77 (2): 181-90
40. Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand 2000 Jun; 101 (6): 359-71
41. Baba H, Ji RR, Kohno T, et al. Removal of GABAergic inhibition facilitates polysynaptic A fiber-mediated excitatory transmission to the superficial spinal dorsal horn. Mol Cell Neurosci 2003 Nov; 24 (3): 818-30
42. Pardo CA, McArthur JC, Griffin JW. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst 2001; 6: 21-7
43. Apostolski S, McAlarney T, Quattrini A, et al. The gp120 glycoprotein of human immunodeficiency virus type 1 binds to sensory ganglian neurons. Ann Neurol 1993 Dec; 34 (6): 855-63
44. Herzberg U, Sagen J. Peripheral nerve exposure to HIV viral envelope protein gp120 induces neuropathic pain and spinal gliosis. J Neuroimmunol 2001; 116: 29-39
45. Oh SB, Tran PB, Gillard SE, et al. Chemokines and glycoprotein 120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci 2001; 21 (14): 5027-35
46. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003 Nov; 60 (11): 1524-34
47. Verma S, Micsa E, Estanislao L. Neuromuscular complications in HIV. Curr Neurol Neurosci Rep 2004; 4: 62-7
48. Breen EC. Pro- and anti-inflammatory cytokines in human immunodeficiency virus infection and acquired immunodeficiency syndrome. Pharmacol Ther 2002; 3: 295-304
49. Power C, Gill MJ, Johnson RT. Progress in clinical neurosciences. The neuropathogenesis of HIV infection: host-virus interaction and the impact of therapy. Can J Neurol Sci 2002; 1: 19-32
50. Nagano I, Shapshak P, Yoshioka M, et al. Increased NADPH-diaphrose reactivity and cytokine expression in dorsal root ganglia in acquired immunodeficiency syndrome. J Neuro Sci 1996 Mar; 136(1-2): 117-28
51. Yoshioka M, Shapshak P, Srivastava AK, et al. Expression of HIV-1 and interleukin-6 in lumbosacral dorsal root ganglia of patients with AIDS. Neurology 1994 Jun; 44 (6): 1120-30
52. Scaravilli F, Sinclair E, Arango JC, et al. The pathology of the posterior root ganglia in AIDS and its relationship to the pallor of the gracile tract. Acta Neuropathol (Berl) 1992; 84 (2): 163-70
53. Moyle GJ. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000; 22: 911-36
54. Lewis W, Dalakas M. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1: 417-22
55. Cherry CL, McArthur JC, Hoy JF, et al. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol 2003; 26 (2): 195-207
56. Dalakas M, Semino-Mora C, Leon-Monzon M, et al. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3'-dideoxycytidine (ddC). Lab Invest 2001; 81 (11): 1537-44
57. McKay Hart A, Wiberg M, Terenghi G. Pharmacological enhancement of peripheral nerve regeneration in the rat by systemic acetyl-L-carnitine treatment. Neurosci Lett 2002 Dec 16; 334 (3): 181-5
58. Colucci WJ, Gandour RD. Carnitine acetyltransferase: a review of its biology, enzymology and bioorganic chemistry. Bioorg Chem 1988; 16; 307-34
59. Famularo G, Moretti S, Marcellini S, et al. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogs. AIDS 1997; 11: 185-90
60. Simpson DM, Katzenstein D, Haidich B, et al. Plasma carnitine in HIV-associated neuropathy. AIDS 2001; 15 (16): 2207-8
61. Verma S, Micsa E, Estanislao L, et al. Neuromuscular complications in HIV. Curr Neurol Neurosci Rep 2004; 1: 62-7
62. Cornblath DR, McArthur JC. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 1988; 38 (5): 794-6
63. Watters MR, Poff PW, Shiramizu BT, et al. Symptomatic distal sensory polyneuropathy in HIV after age 50. Neurology 2004 Apr 27; 62 (8): 1378-83
64. Verma A. Epidemiology and clinical features of HIV-1 associated neuropathies. J Peripher Nerv Syst 2001 Mar; 6 (1): 8-13
65. Kieburtz K, Seidlin M, Lambert J. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. J AIDS 1992; 5: 60-4
66. Breitbart W, Rosenfeld BD, Passik SD, et al. The undertreatment of pain in ambulatory AIDS patients. Pain 1996 May-Jun; 65 (2-3): 243-9
67. Breitbart W, Kairn M, Rosenfeld B. Clinicians' perceptions of barriers to pain management in AIDS. J Pain Symptom Manage 1999 Sep; 18 (3): 203-11
68. Breitbart W, Passik S, McDonald MV, et al. Patient-related barriers to pain management in ambulatory AIDS patients. Pain 1998 May; 76 (1-2): 9-16
69. Haythornthwaite JA, Benrud-Larson LM. Psychological assessment and treatment of patients with neuropathic pain. Curr Pain Headache Rep 2001; 5 (2): 124-9
70. Forst T, Nguyen M, Forst S, et al. Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device. Diabetes Nutr Metab 2004 Jun; 17 (3): 163-8
71. Chavez C. Prickly business: the finer points of acupuncture. Posit Aware 1995 Jan-Feb; 14-5
72. Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. JAMA 1998; 280: 1590-5
73. Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 1998; 51 (6): 1682-8
74. Simpson D, Olney R, McArthur JC, et al. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 2000; 54: 2115-9
75. Simpson DM, McArthur JC, Olney R, et al. Lamotrigine HIV Neuropathy Study Team. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 2003 May 13; 60 (9): 1508-14
76. Phillips WJ, Currier BL. Analgesic pharmacology: II. Specific analgesics. J Am Acad Orthop Surg 2004 Jul-Aug; 12 (4): 221-33
77. Backonja M, Malan P, Brady S, et al. One-hour high-concentration trans-capsaicin applications provide durable pain relief in initial and repeat treatment of postherpetic neuralgia (PHN) [abstract no. S51.002]. American Academy of Neurology 56th Annual Meeting; 2004 Apr 24-May 1; San Francisco
78. Simpson D, Brown S, Sampson J, et al. A single application of high concentration trans-capsaicin leads to 12 weeks of pain relief in HIV DSP: results of an open label trial [presentation]. American Academy of Neurology 56th Annual Meeting; 2004 Apr 24-May 1; San Francisco
79. Fichtenbaum CJ, Clifford DB, Powderly WG. Risk factors for dideoxynucleoside induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 169-74
80. Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. Neurology 1998; 51: 1682-8
81. Simpson DM. Selected peripheral neuropathies associated with human immunodeficiency virus infection and antiretroviral therapy. J Neurovirol 2002 Dec; 8 Suppl. 2: 33-41
82. Kolson DL, Gonzalez-Scarano F. HIV-associated neuropathies: role of HIV-1, CMV, and other viruses. J Peripher Nerv Syste 2001 Mar; 6(1): 2-7
83. Wulff EA, Wang AK, Simpson DM. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs 2000 Jun; 59 (6): 1251-60
84. Gozlan J, Amrani M, Baudrimont M, et al. A prospective evaluation of clinical criteria and polymerase chain reaction assay of cerebrospinal fluid for the diagnosis of cytomegalovirus-related neurological diseases during AIDS. AIDS 1995 Mar; 9 (3): 253-60
85. Gozlan J, Salord JM, Roullet E, et al. Rapid detection of cytomegalovirus. J Infect Dis 1992 Dec; 166 (6): 1416-21
86. Cornford ME, Ho HW, Vinters HV. Correlation of neuromuscular pathology in acquired immune deficency syndrome patients with cytomegalovirus infection and zidovudine treatment. Acta Neuropathol (Berl) 1992; 84 (5): 516-29
87. Periquet MI, Novak V, Collins MP, et al. Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology 1999; 53: 1641-7
88. Tominaga M, Caterina MJ, Malmberg AB, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998 Sep; 21 (3): 531-43
89. Nolano M, Simone DA, Wendelschafer-Crabb G, et al. Topical capsaicin in humans; parallel loss of epidermal nerve fibers and pain sensation. Pain 1999 May; 81 (1-2): 135-45
90. McArthur JC, Tiannoutsos C, Simpson DM, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 2000; 54 (5): 1080-8
91. Simpson D, Dorfman D, Olney R, et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Neurology 1996; 47: 1254-9
92. Campana WM, Eskeland N, Calcutt NA, et al. Prosaptide prevents paclitaxel neurotoxicity. Neurotoxicology 1998 Apr; 19 (2): 237-44
93. Yan L, Otero DA, Hiraiwa M, et al. Prosaptide D5 reverses hyperalgesia: inhibition rat. Neurosci Lett 2000 Jan; 278 (1-2): 120-2
94. Editorial. New advances promising in treating neuropathy: experts explain what's the latest and best. AIDS Alert 2004 Mar; 19 (3): 31-3